[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Hanley Jr. Michael Conick
Role
CHIEF OPERATING OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 8,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 8,000 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 188,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 188,000 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 125,000 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 125,000 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 8,000 shares (Direct)
Footnotes (1)
- The shares subject to the option are fully vested and exercisable. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
